An extremely potent and clinically significant biomarker for pancreatic cancer has been identified that offers efficient early diagnosis and thus better prognosis. This article discusses the benefit of this novel biomarker. Pancreatic cancer accounts for the top-five leading cause of cancer death owing to its less than 4% five-year survival rate even with modern surgical techniques.
Diagnosis in the advanced stage is the key reason for the poor prognosis. Surveys reveal that only 10% pancreatic cancer is resectable since 90% of cases are diagnosed at the unresectable stage of III/IV. Although CA19-9 is the current widely used biomarker for pancreatic cancer, it has some limitations: CA19-9 fails to identify patients with small resectable tumor Chances of falls & nonspecific diagnosis Fails to precisely detect cancer early Researchers have identified and clinically proven the efficacy of…
